Astrazeneca (AZN) Cash from Investing Activities (2009 - 2026)

Astrazeneca (AZN) has reported Cash from Investing Activities for 17 consecutive years, with -$1.8 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 43.02% year-over-year to -$1.8 billion; the TTM figure through Mar 2026 stood at -$7.3 billion (down 7.73% YoY), while the FY2025 annual figure was -$6.8 billion, up 14.69% from the prior year.
• Cash from Investing Activities came in at -$1.8 billion for Q1 2026 at Astrazeneca, down from -$1.4 billion in the prior quarter.
• The five-year high for Cash from Investing Activities was -$168.0 million in Q1 2022, with the low at -$2.9 billion in Q2 2024.
• Average Cash from Investing Activities over 5 years is -$1.5 billion, with a median of -$1.4 billion recorded in 2025.
• Across the five-year window, Cash from Investing Activities tumbled 641.67% in 2023 and jumped 48.07% in 2025, its largest moves.
• Year by year, Cash from Investing Activities stood at -$800.0 million in 2022, then surged by 35.0% to -$520.0 million in 2023, then tumbled by 127.12% to -$1.2 billion in 2024, then decreased by 22.44% to -$1.4 billion in 2025, then decreased by 23.93% to -$1.8 billion in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered -$1.8 billion, -$1.4 billion, and -$2.0 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.